Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in
VAN00013
Phase 2 small_molecule active
Quick answer
Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in for Meningococcal immunization is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Meningococcal immunization
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active